INVESTOR RESOURCES
iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS
Corporate Overview
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions. They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure. The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost. The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.
iCHOR at LSI '24
Medline Review Articles
The Latest News
Explore iCHOR's New FAQ Sections
As an outgrowth of iCHOR’s evolution in leading the way on transformation of the peripheral thrombectomy sector, we are constantly being asked questions about both the big picture regarding market changes and specific details about how ICHOR fits into the changing landscape. To make it easier for everyone to quickly find the answers, we’ve pulled together a comprehensive set of…
Simplified Mechanical Thrombectomy Opens New Opportunities for ASCs and OBLs
Ambulatory Surgery Centers (ASCs) and Office-Based Labs (OBLs) are emerging as compelling alternatives to hospital-based care, offering patients better access at substantially lower cost. As site-of-care reimbursement evolves and technology matures, peripheral thrombectomy is now becoming economically viable in these settings. iCHOR Vascular’s iSWEEP platform is accelerating this shift through intentional simplicity: no capital equipment, minimal setup, predictable costs, and…